Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PHENURONE vs BRIVARACETAM
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Phenurone (phenacemide) is an anticonvulsant that reduces neuronal excitability by inhibiting voltage-gated sodium channels and potentiating GABAergic inhibition. It also has a structure similar to other hydantoins and may increase the seizure threshold.
Brivaracetam is a high-affinity synaptic vesicle glycoprotein 2A (SV2A) ligand, binding to SV2A with 15- to 30-fold higher affinity than levetiracetam. It modulates neurotransmitter release, reducing neuronal excitability. It also inhibits voltage-gated sodium channels at clinically relevant concentrations.
Adjunctive therapy in the treatment of partial seizures with or without secondary generalization,Off-label: refractory epilepsy, complex partial seizures
Adjunctive therapy in the treatment of partial-onset seizures (POS) in patients 4 years of age and older with epilepsy
Adults: 500 mg to 1 g orally twice daily, increased gradually up to 3 g/day in divided doses.
50 mg orally twice daily, with or without food. May increase to 100 mg twice daily based on tolerability and efficacy. Maximum 200 mg twice daily.
The terminal elimination half-life is approximately 22-35 hours in adults. This long half-life supports once- or twice-daily dosing, but requires careful monitoring for accumulation.
Terminal elimination half-life is approximately 9 hours in adults with normal renal function. In patients with severe renal impairment (Cr Cl <30 m L/min), half-life is prolonged to about 20-30 hours, requiring dose adjustment.
Primarily hepatic metabolism via hydrolysis and conjugation; involves CYP450 enzymes (minor contribution). Metabolites are excreted in urine.
Brivaracetam is primarily metabolized by hydrolysis of the acetamide group via amide bond hydrolysis (not cytochrome P450), forming the inactive carboxylic acid metabolite (M1). A minor pathway is hydroxylation via CYP2C19, producing the hydroxyl metabolite (M2).
Phenurone is extensively metabolized in the liver; less than 1% is excreted unchanged in urine. The primary metabolite is 4-hydroxyphenylethylhydantoin (p-HPEH). Renal excretion accounts for approximately 70-80% of the dose, mainly as metabolites; the remainder is eliminated via bile/feces. Enterohepatic circulation may occur.
Approximately 95% of the dose is excreted renally, with about 8-12% as unchanged drug and the remainder as metabolites (primarily by hydrolysis to the carboxylic acid metabolite). Fecal excretion accounts for less than 1%.
Approximately 80-90% bound, primarily to serum albumin. The binding is saturable, which can lead to nonlinear pharmacokinetics at high doses.
Less than 20% bound to plasma proteins (primarily albumin and alpha-1-acid glycoprotein). Binding is concentration-independent and low, minimizing displacement interactions.
0.5-1.0 L/kg. This moderate Vd indicates distribution into total body water and some tissue binding. Vd may be increased in epilepsy or with co-administration of other anticonvulsants.
Volume of distribution is approximately 0.5 L/kg (range 0.3-0.6 L/kg), indicating distribution into total body water with moderate tissue binding.
Oral bioavailability is approximately 90-100% based on absorption studies. Food does not significantly affect absorption.
Oral bioavailability is approximately 90% (range 80-100%), with rapid absorption. Food does not significantly affect absorption. Absolute bioavailability is 100% for intravenous administration.
No specific guidelines; use with caution in renal impairment. Monitor for toxicity.
Cr Cl ≥50 m L/min: no adjustment. Cr Cl 30-49 m L/min: 25-50 mg twice daily. Cr Cl 15-29 m L/min: 12.5-25 mg twice daily. Cr Cl <15 m L/min: 12.5-25 mg once daily. Hemodialysis: 12.5-25 mg once daily, with supplemental dose after dialysis.
Child-Pugh Class A: No adjustment; Class B: Reduce dose by 25-50%; Class C: Avoid use.
Child-Pugh A: no adjustment. Child-Pugh B: 12.5-25 mg twice daily, initial dose 12.5 mg twice daily. Child-Pugh C: not recommended.
Children: 10-20 mg/kg/day orally in 2-3 divided doses; maximum 1.5 g/day.
Age ≥1 month to <16 years: weight-based dosing. Initially 1.25 mg/kg twice daily, maximum 2.5 mg/kg twice daily. Total daily dose range: 2.5-5 mg/kg/day. Maximum 200 mg/day.
Initiate at low end of dosing range (500 mg/day) and titrate slowly; monitor for neurotoxicity.
Initiate at lower dose (12.5-25 mg twice daily) due to decreased renal function; titrate slowly. Monitor renal function and neuropsychiatric effects.
Phenacemide may cause fatal hepatotoxicity and aplastic anemia. Patients must be closely monitored for signs of hepatic dysfunction and blood dyscrasias.
None
Hepatotoxicity: monitor liver function tests at baseline and periodically; discontinue if signs of hepatic injury. Aplastic anemia: advise patients to report unexplained bleeding, bruising, or signs of infection. Suicidal ideation: monitor for changes in mood or behavior. Withdrawal: do not discontinue abruptly.
Suicidal ideation and behavior: Monitor for emergence or worsening of depression, suicidal thoughts/behavior, or unusual mood changes.,Neurological adverse reactions: Dizziness, somnolence, and coordination difficulties (ataxia, gait disturbance, vertigo).,Withdrawal: Abrupt discontinuation may precipitate withdrawal seizures; taper gradually.
History of liver disease or hepatic dysfunction. History of aplastic anemia or bone marrow depression. Hypersensitivity to phenacemide or other hydantoins. Concurrent use with other hepatotoxic drugs.
Hypersensitivity to brivaracetam or any of its inactive ingredients
No significant food interactions documented. Avoid alcohol entirely due to additive CNS depression and potential hepatotoxicity.
No significant food interactions. Alcohol may increase central nervous system depression; avoid or limit alcohol consumption.
Category D: Increased risk of neural tube defects, cleft palate, and congenital heart defects. Avoid in first trimester; use only if benefit outweighs risk in later trimesters.
First trimester: Limited human data; animal studies show increased fetal malformations (e.g., skeletal abnormalities) at clinically relevant doses. Second and third trimesters: Potential for neurodevelopmental effects; avoid use unless benefit outweighs risk. Overall: Considered possibly teratogenic (FDA Pregnancy Category C equivalent).
Excreted into breast milk; M/P ratio unknown. Avoid breastfeeding due to potential for adverse effects (e.g., sedation, poor feeding) in the infant.
Brivaracetam is excreted into human breast milk with a milk-to-plasma (M/P) ratio of approximately 1.0. Infant exposure estimated at 0.5-1% of maternal weight-adjusted dose. Monitor infant for sedation, poor feeding, and weight gain. Benefit of breastfeeding may outweigh risks with caution.
Due to increased clearance in pregnancy, monitor serum concentrations and adjust dose to maintain therapeutic levels; may require dose increases by 20-30%.
Pregnancy can decrease brivaracetam concentrations by 30-40% due to increased clearance and volume of distribution. Monitor clinical response and consider therapeutic drug monitoring to maintain trough levels within non-pregnant target range (0.5-10 mcg/m L). May require dose increase of 50-100% in second and third trimesters. Postpartum: Reduce dose to pre-pregnancy levels over 1-2 weeks to avoid toxicity.
Phenurone (phenacemide) is a last-line anticonvulsant due to high risk of hepatotoxicity and bone marrow suppression. Monitor LFTs and CBC monthly. Avoid in patients with liver disease or history of psychosis. Therapeutic drug monitoring: target serum phenacemide level 5-12 mcg/m L. May cause severe personality changes and suicidal ideation.
Brivaracetam is a SV2A ligand with higher affinity and selectivity than levetiracetam. It does not require dose adjustment in renal impairment unless creatinine clearance <30 m L/min. Do not use in patients with hepatic impairment. Onset of action is rapid; oral and IV formulations are bioequivalent. Monitor for psychiatric symptoms (e.g., aggression, psychosis) and somnolence. No need for titration; starting dose 50-100 mg/day divided twice daily.
Take exactly as prescribed; do not adjust dose without consulting your doctor.,Report signs of liver injury (yellow skin/eyes, dark urine, abdominal pain) or blood dyscrasias (fever, sore throat, easy bruising) immediately.,Avoid alcohol completely while taking this medication.,May cause drowsiness or dizziness; avoid driving until you know how this drug affects you.,Use reliable contraception; phenacemide can harm a fetus and decrease effectiveness of hormonal contraceptives.,Do not stop abruptly; withdrawal can precipitate seizures.
Take brivaracetam exactly as prescribed, with or without food.,Do not stop taking this medication suddenly, as it may increase seizure frequency.,Report any mood changes, aggression, or thoughts of self-harm immediately.,May cause drowsiness or dizziness; avoid driving until you know how it affects you.,If you have liver disease, inform your doctor before starting brivaracetam.,Store at room temperature, away from moisture and heat.
No interactions on record
"Mianserin, a tetracyclic antidepressant with strong antihistaminergic and alpha2-adrenergic antagonist properties, may reduce the anticonvulsant efficacy of brivaracetam. By blocking presynaptic alpha2-adrenoceptors, mianserin enhances norepinephrine release, which can modulate neuronal excitability and potentially counteract the synaptic vesicle protein 2A (SV2A) binding mechanism of brivaracetam. This pharmacodynamic opposition may lead to increased seizure frequency or breakthrough seizures in patients with epilepsy when coadministered."
"Pentobarbital, a potent enzyme-inducing barbiturate, significantly increases the hepatic metabolism of brivaracetam, a second-generation antiepileptic drug, via induction of CYP3A4 and other metabolic enzymes. This interaction leads to reduced plasma concentrations of brivaracetam, potentially diminishing its antiseizure efficacy and increasing the risk of breakthrough seizures. Clinically, patients may require dose adjustment of brivaracetam or alternative therapy to maintain therapeutic effect."
"Brivaracetam may inhibit the metabolism of diltiazem, a calcium channel blocker, primarily via competition for CYP3A4 enzyme, leading to increased plasma concentrations of diltiazem. This can potentiate its therapeutic and adverse effects, including bradycardia, hypotension, and atrioventricular block. Clinical outcomes may include enhanced antihypertensive efficacy or increased risk of heart block, particularly in patients with pre-existing conduction abnormalities."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PHENURONE vs BRIVARACETAM, answered by our medical review team.
PHENURONE is a Anticonvulsant that works by Phenurone (phenacemide) is an anticonvulsant that reduces neuronal excitability by inhibiting voltage-gated sodium channels and potentiating GABAergic inhibition. It also has a structure similar to other hydantoins and may increase the seizure threshold.. BRIVARACETAM is a Anticonvulsant that works by Brivaracetam is a high-affinity synaptic vesicle glycoprotein 2A (SV2A) ligand, binding to SV2A with 15- to 30-fold higher affinity than levetiracetam. It modulates neurotransmitter release, reducing neuronal excitability. It also inhibits voltage-gated sodium channels at clinically relevant concentrations.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PHENURONE and BRIVARACETAM depend on the specific clinical indication. These are both Anticonvulsant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PHENURONE is: Adults: 500 mg to 1 g orally twice daily, increased gradually up to 3 g/day in divided doses.. The standard adult dose of BRIVARACETAM is: 50 mg orally twice daily, with or without food. May increase to 100 mg twice daily based on tolerability and efficacy. Maximum 200 mg twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PHENURONE and BRIVARACETAM in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PHENURONE is classified as Category C. Category D: Increased risk of neural tube defects, cleft palate, and congenital heart defects. Avoid in first trimester; use only if benefit outweighs risk in later trimesters.. BRIVARACETAM is classified as Category C. First trimester: Limited human data; animal studies show increased fetal malformations (e.g., skeletal abnormalities) at clinically relevant doses. Second and third trimesters: Pot. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.